Axonics (AXNX) Stock Forecast, Price Target & Predictions
AXNX Stock Forecast
Axonics stock forecast is as follows: an average price target of $71.00 (represents a 0.88% upside from AXNX’s last price of $70.38) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
AXNX Price Target
The average price target for Axonics (AXNX) is $71.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $71.00 to $71.00. This represents a potential 0.88% upside from AXNX's last price of $70.38.
AXNX Analyst Ratings
According to 6 Wall Street analysts, Axonics's rating consensus is 'Buy'. The analyst rating breakdown for AXNX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Axonics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Adam Maeder | Piper Sandler | $71.00 | $69.31 | 2.44% | 0.88% |
The latest Axonics stock forecast, released on Sep 19, 2024 by Adam Maeder from Piper Sandler, set a price target of $71.00, which represents a 2.44% increase from the stock price at the time of the forecast ($69.31), and a 0.88% increase from AXNX last price ($70.38).
Axonics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $71.00 | $71.00 |
| Last Closing Price | $70.38 | $70.38 | $70.38 |
| Upside/Downside | -100.00% | 0.88% | 0.88% |
In the current month, the average price target of Axonics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Axonics's last price of $70.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Feb 29, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Jul 13, 2023 | KeyBanc | - | Overweight | Initialise |
| Mar 24, 2023 | Needham | - | Buy | Upgrade |
| Oct 05, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 02, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Feb 25, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Axonics's last stock rating was published by Piper Sandler on Sep 19, 2024. The company gave AXNX a "Neutral" rating, the same as its previous rate.
Axonics Financial Forecast
Axonics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $93.10M | $22.70M | $70.65M | $85.92M | $70.38M | $68.98M | $48.42M | $53.13M | $46.91M | $45.87M | $34.37M | $34.78M | $35.24M | $15.21M | $26.30M | $9.95M | $1.31M |
| Avg Forecast | $180.99M | $153.68M | $157.36M | $125.39M | $159.74M | $136.50M | $136.45M | $108.45M | $130.80M | $113.36M | $112.83M | $89.79M | $107.33M | $89.59M | $86.45M | $64.43M | $82.22M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| High Forecast | $180.99M | $153.68M | $157.36M | $125.39M | $159.74M | $136.50M | $136.45M | $108.45M | $130.80M | $114.82M | $112.83M | $89.79M | $107.50M | $89.59M | $86.45M | $64.43M | $82.22M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| Low Forecast | $180.99M | $153.68M | $157.36M | $125.39M | $159.74M | $136.50M | $136.45M | $108.45M | $130.80M | $111.93M | $112.83M | $89.79M | $107.01M | $89.59M | $86.45M | $64.43M | $82.22M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.26% | 1.10% | 1.04% | 1.11% | 1.16% | 1.07% | 1.05% | 0.97% | 1.15% | 1.23% | 0.99% | 1.54% | 2.93% | 1.80% | 0.99% | 0.92% |
Axonics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $107.33M, with a low forecast of $107.01M, and a high forecast of $107.50M. AXNX's average Quarter revenue forecast represents a 15.29% increase compared to the company's last Quarter revenue of $93.10M (Sep 23).
Axonics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-687.00K | $22.31M | $-8.61M | $2.96M | $-4.32M | $-5.97M | $-20.46M | $-15.11M | $-13.80M | $-13.34M | $-20.48M | $-10.41M | $-8.29M | $-18.91M | $-13.68M | $-21.88M | $-24.11M |
| Avg Forecast | $-68.30M | $-57.99M | $-59.38M | $-47.32M | $-60.28M | $-51.51M | $-51.49M | $-40.93M | $-49.36M | $-42.78M | $-42.58M | $-29.87M | $-40.50M | $-33.81M | $-32.62M | $-27.15M | $-17.97M | $-23.97M | $-22.49M | $-24.68M | $-19.01M | $-18.26M | $-15.03M | $-12.48M | $-13.32M | $-8.66M | $-1.96M | $-17.56M | $-3.77M | $-534.80K |
| High Forecast | $-68.30M | $-57.99M | $-59.38M | $-47.32M | $-60.28M | $-51.51M | $-51.49M | $-40.93M | $-49.36M | $-42.24M | $-42.58M | $-23.89M | $-40.38M | $-33.81M | $-32.62M | $-21.72M | $-14.38M | $-23.97M | $-22.49M | $-19.75M | $-19.01M | $-18.26M | $-15.03M | $-9.99M | $-13.32M | $-8.66M | $-1.96M | $-14.05M | $-3.77M | $-534.80K |
| Low Forecast | $-68.30M | $-57.99M | $-59.38M | $-47.32M | $-60.28M | $-51.51M | $-51.49M | $-40.93M | $-49.36M | $-43.33M | $-42.58M | $-35.84M | $-40.56M | $-33.81M | $-32.62M | $-32.58M | $-21.57M | $-23.97M | $-22.49M | $-29.62M | $-19.01M | $-18.26M | $-15.03M | $-14.98M | $-13.32M | $-8.66M | $-1.96M | $-21.07M | $-3.77M | $-534.80K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.02% | -0.68% | 0.32% | -0.16% | 0.18% | 0.27% | 0.83% | 0.80% | 0.76% | 0.89% | 1.64% | 0.78% | 0.96% | 9.66% | 0.78% | 5.80% | 45.08% |
4 analysts predict AXNX's average Quarter EBITDA for Sep 23 to be $-33.81M, with a high of $-33.81M and a low of $-33.81M. This is -251.56% lower than Axonics's previous annual EBITDA (Jun 23) of $22.31M.
Axonics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.93M | $-7.34M | $-9.25M | $665.00K | $-16.25M | $-21.44M | $-22.67M | $-15.17M | $-17.25M | $-25.15M | $-22.50M | $-11.35M | $-9.17M | $-19.78M | $-14.62M | $-22.75M | $-25.01M |
| Avg Forecast | $21.05M | $11.62M | $12.02M | $-1.56M | $20.88M | $10.37M | $12.50M | $-2.46M | $12.14M | $5.75M | $5.03M | $-33.09M | $3.30M | $-2.62M | $-6.03M | $-30.08M | $-18.04M | $-23.84M | $-28.10M | $-27.35M | $-18.41M | $-21.94M | $-25.15M | $-13.72M | $-15.82M | $-26.88M | $-33.27M | $-18.76M | $-36.68M | $-38.28M |
| High Forecast | $21.05M | $11.62M | $12.02M | $-1.56M | $20.88M | $10.37M | $12.50M | $-2.46M | $12.14M | $8.85M | $5.03M | $-26.47M | $5.51M | $-2.62M | $-6.03M | $-24.06M | $-14.43M | $-23.84M | $-28.10M | $-21.88M | $-18.41M | $-21.94M | $-25.15M | $-10.98M | $-15.82M | $-26.88M | $-33.27M | $-15.01M | $-36.68M | $-38.28M |
| Low Forecast | $21.05M | $11.62M | $12.02M | $-1.56M | $20.88M | $10.37M | $12.50M | $-2.46M | $12.14M | $3.10M | $5.03M | $-39.71M | $1.10M | $-2.62M | $-6.03M | $-36.10M | $-21.64M | $-23.84M | $-28.10M | $-32.81M | $-18.41M | $-21.94M | $-25.15M | $-16.47M | $-15.82M | $-26.88M | $-33.27M | $-22.51M | $-36.68M | $-38.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.50% | 1.22% | 0.31% | -0.04% | 0.68% | 0.76% | 0.83% | 0.82% | 0.79% | 1.00% | 1.64% | 0.72% | 0.34% | 0.59% | 0.78% | 0.62% | 0.65% |
Axonics's average Quarter net income forecast for Dec 23 is $3.30M, with a range of $1.10M to $5.51M. AXNX's average Quarter net income forecast represents a -15.86% decrease compared to the company's last Quarter net income of $3.93M (Sep 23).
Axonics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $59.32M | $54.98M | $54.82M | $54.09M | $49.14M | $49.95M | $43.08M | $40.74M | $36.83M | $33.45M | $27.55M | $24.87M | $22.83M | $19.76M | $24.22M | $21.84M | $20.87M |
| Avg Forecast | $284.23M | $241.34M | $247.12M | $196.92M | $250.87M | $214.37M | $214.29M | $170.32M | $205.40M | $178.03M | $177.20M | $62.88M | $168.56M | $140.70M | $135.76M | $57.16M | $48.45M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $16.80M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| High Forecast | $284.23M | $241.34M | $247.12M | $196.92M | $250.87M | $214.37M | $214.29M | $170.32M | $205.40M | $180.31M | $177.20M | $75.45M | $168.82M | $140.70M | $135.76M | $68.59M | $58.14M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $20.16M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| Low Forecast | $284.23M | $241.34M | $247.12M | $196.92M | $250.87M | $214.37M | $214.29M | $170.32M | $205.40M | $175.77M | $177.20M | $50.30M | $168.05M | $140.70M | $135.76M | $45.73M | $38.76M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $13.44M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.42% | 0.41% | 0.96% | 1.12% | 0.49% | 0.53% | 0.60% | 0.52% | 0.48% | 0.53% | 1.64% | 0.45% | 0.63% | 2.42% | 1.05% | 1.39% | 9.38% |
Axonics's average Quarter SG&A projection for Dec 23 is $168.56M, based on 8 Wall Street analysts, with a range of $168.05M to $168.82M. The forecast indicates a 184.14% rise compared to AXNX last annual SG&A of $59.32M (Sep 23).
Axonics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.08 | $-0.15 | $-0.19 | $0.01 | $-0.34 | $-0.47 | $-0.50 | $-0.34 | $-0.38 | $-0.59 | $-0.57 | $-0.29 | $-0.24 | $-0.54 | $-0.43 | $-0.75 | $-0.89 |
| Avg Forecast | $0.41 | $0.23 | $0.23 | $-0.03 | $0.41 | $0.20 | $0.24 | $-0.05 | $0.24 | $0.11 | $0.10 | $-0.06 | $0.06 | $-0.05 | $-0.12 | $-0.29 | $-0.24 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| High Forecast | $0.41 | $0.23 | $0.23 | $-0.03 | $0.41 | $0.20 | $0.24 | $-0.05 | $0.24 | $0.17 | $0.10 | $-0.06 | $0.11 | $-0.05 | $-0.12 | $-0.29 | $-0.24 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| Low Forecast | $0.41 | $0.23 | $0.23 | $-0.03 | $0.41 | $0.20 | $0.24 | $-0.05 | $0.24 | $0.06 | $0.10 | $-0.06 | $0.02 | $-0.05 | $-0.12 | $-0.29 | $-0.24 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.56% | 1.27% | 0.66% | -0.04% | 0.73% | 0.86% | 0.79% | 0.95% | 0.89% | 1.20% | 1.40% | 0.94% | 0.46% | 0.83% | 0.72% | 1.05% | 1.19% |
According to 8 Wall Street analysts, Axonics's projected average Quarter EPS for Dec 23 is $0.06, with a low estimate of $0.02 and a high estimate of $0.11. This represents a -19.16% decrease compared to AXNX previous annual EPS of $0.08 (Sep 23).
Axonics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NNOX | Nano-X Imaging | $5.67 | $18.00 | 217.46% | Buy |
| NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
| OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
| IART | Integra LifeSciences | $24.12 | $43.00 | 78.28% | Sell |
| LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
| IRTC | iRhythm | $81.44 | $121.17 | 48.78% | Buy |
| SIBN | SI-BONE | $13.63 | $20.00 | 46.74% | Buy |
| LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
| KIDS | OrthoPediatrics | $28.74 | $39.60 | 37.79% | Buy |
| CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
| BRKR | Bruker | $59.35 | $73.75 | 24.26% | Buy |
| MDT | Medtronic | $89.31 | $107.91 | 20.83% | Hold |
| ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
| AXNX | Axonics | $70.38 | $71.00 | 0.88% | Buy |
| GKOS | Glaukos | $131.38 | $119.33 | -9.17% | Buy |
AXNX Forecast FAQ
Is Axonics a good buy?
Yes, according to 6 Wall Street analysts, Axonics (AXNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of AXNX's total ratings.
What is AXNX's price target?
Axonics (AXNX) average price target is $71 with a range of $71 to $71, implying a 0.88% from its last price of $70.38. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Axonics stock go up soon?
According to Wall Street analysts' prediction for AXNX stock, the company can go up by 0.88% (from the last price of $70.38 to the average price target of $71), up by 0.88% based on the highest stock price target, and up by 0.88% based on the lowest stock price target.
Can Axonics stock reach $110?
AXNX's average twelve months analyst stock price target of $71 does not support the claim that Axonics can reach $110 in the near future.
What are Axonics's analysts' financial forecasts?
Axonics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $541.16M (high $541.16M, low $541.16M), average EBITDA is $-204M (high $-204M, low $-204M), average net income is $41.29M (high $41.29M, low $41.29M), average SG&A $849.84M (high $849.84M, low $849.84M), and average EPS is $0.806 (high $0.806, low $0.806). AXNX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $617.42M (high $617.42M, low $617.42M), average EBITDA is $-233M (high $-233M, low $-233M), average net income is $43.14M (high $43.14M, low $43.14M), average SG&A $969.61M (high $969.61M, low $969.61M), and average EPS is $0.842 (high $0.842, low $0.842).
Did the AXNX's actual financial results beat the analysts' financial forecasts?
Based on Axonics's last annual report (Dec 2023), the company's revenue was $366.38M, beating the average analysts forecast of $347.8M by 5.34%. Apple's EBITDA was $-26.057M, missing the average prediction of $-134M by -80.57%. The company's net income was $-6.088M, missing the average estimation of $-35.424M by -82.81%. Apple's SG&A was $235.32M, missing the average forecast of $502.18M by -53.14%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.391 by -99.97%. In terms of the last quarterly report (Sep 2023), Axonics's revenue was $93.1M, beating the average analysts' forecast of $89.59M by 3.91%. The company's EBITDA was $-687K, missing the average prediction of $-33.808M by -97.97%. Axonics's net income was $3.93M, missing the average estimation of $-2.615M by -250.19%. The company's SG&A was $59.32M, missing the average forecast of $140.7M by -57.84%. Lastly, the company's EPS was $0.0798, missing the average prediction of $-0.051 by -256.32%